To
The Members,
Aspira Pathlab & Diagnostics Limited
Your Directors take pleasure in presenting 53rd Annual Report on the
business and operations of the Company along with the Audited Financial Statements for the
year ended March 31, 2026
The key highlights of the Audited Financial Statements of the Company's for the
financial year ended March 31, 2026 in comparison with the previous financial year ended
March 31, 2025 are summarized below summarized below:
(Rs. In Lakhs)
Particulars |
Standalone |
|
2025-26 |
2024-25 |
| Revenue from Operations |
2498.20 |
2,199.90 |
| Other Income |
51.59 |
38.89 |
Total Income |
2549.79 |
2,238.79 |
| Depreciation and amortisation expenses |
153.84 |
149.38 |
| Other Expenses |
888.60 |
1882.15 |
Total Expenses |
2544.67 |
2031.53 |
Profit/(Loss) before exceptional items and tax |
5.13 |
207.26 |
| Exceptional items |
|
|
Profit/(Loss) before tax |
5.13 |
207.30 |
| Tax expense/(credit) |
11.25 |
207.30 |
Profit/(Loss) after exceptional items and tax |
5.13 |
207.30 |
CHANGE IN NATURE OF BUSINESS
The Company is primarily engaged in the activities of pathology and related healthcare
services. There was no change in nature of the business of the Company, during the year
under review.
FINANCIAL PERFORMANCE
During the year under review the total income of the Company is Rs. 2498.20 lakhs as
compared to Rs. 2,199.90 lakhs in previous year, representing profit of Rs. 5.13Lakhs in
the current year.
DIVIDEND
Considering long term prospectus of the Company, the Directors of your Company do not
recommend any dividend for the Financial year 2025-26
TRANSFER TO RESERVE
Your Directors do not propose to transfer any amount to General Reserves for the
financial year 2025-26.
SHARE CAPITAL
During the Financial Year 2025-26, there was no change in the authorized, subscribed,
issued and paid-up share capital of the Company.
SUBSIDIARY/JOINT VENTURES/ ASSOCIATE COMPANIES
As on April 02, 2024 your Company had floated an associate LLP i.e "Aspira DNA
Diagnostics Gujarat LLP". However as on May 16, 2025 Board members had decided to
takeover 100% Assets and Liabilities of Aspira DNA Diagnostics Gujarat LLP by entering
into a business transfer agreement and strike off the LLP as the designated partners of
LLP are unwilling to carry its business in future.
The process for striking off the LLP is currently in process.
However as on 31st March 2026, Your Company does not have any Subsidiary or
Joint Ventures
Pursuant to the provisions of Section 129(3) of the Act, a statement containing the
salient features of financial statements of the Company's Associate in Form No. AOC-1 is
not applicable.
DEPOSITS
During the year under review, your Company has not accepted any deposit from the public
falling within the ambit of Section 73 of the Companies Act, 2013 and the Companies
(Acceptance of Deposits) Rules, 2014
MATERIAL CHANGES AND COMMITMENTS AFFECTING THE FINANCIAL POSITION
There has been no material changes and commitments, since the close of the financial
year i.e. March, 31 2026 till the date of signing of this Directors' Report, affecting the
financial position of your Company.
PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES
The Company has a Related Party Transaction Policy in place which is in accordance with
the SEBI (Listing
Obligation and Disclosure Requirements) Regulations, 2015. The said Policy is available
on the Company's website which can be accessed through the following weblink:
https://www.aspiradiagnostics.com/wp-content/uploads/2025/05/Related-Party-Transaction-Policy-1.pdf
All the Related Party Transactions entered into during the year under review, were
entered in the Ordinary course of business and on an arm's length basis. There were no
materially significant Related Party Transactions made by the Company with its Promoters,
Directors, Key Managerial Personnel or other designated persons which may have a potential
conflict with the interest of the Company at large.
Further, since the transactions with the related parties were in the ordinary course of
business and at arm's length pricing, not material in nature and in accordance with the
Related Party Transactions Policy, the particulars of such transactions with the related
parties are not required to be reported by the Company in E Form AOC-2.
All the Related Party Transactions are reviewed by the Audit Committee and the Board on
a quarterly basis. The members may refer to note no. 39 to the financial statements, which
set out Related Party Disclosures
PARTICULARS OF LOANS, INVESTMENT AND GUARANTEES BY THE COMPANY
In terms of the provisions of section 186 of the Companies Act, 2013 read with
Companies (Meeting of Board and its Powers) Rules, 2014 and Schedule V of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015, loans, guarantees and
investments given/made by the Company as on March 31, 2026 are mentioned in no.6 to the
financial statements of the Company.
PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURES
The disclosures pertaining to remuneration and other details as required under Section
197(12) of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and
Remuneration of Managerial Personnel) Rules, 2014 are provided in the prescribed format
and annexed herewith as Annexure - II to this Annual Report.
The statement containing the names of top ten employees in terms of remuneration drawn
and the particulars of employees as required under Section 197(12) of the Act read with
Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel)
Rules, 2014, is available for inspection and any Member interested in obtaining a copy of
the same may write to the Company Secretary/ Compliance Officer of the Company.
DIRECTORS RETIRING BY ROTATION
Pursuant to the provisions of Section 152 of the Companies Act, 2013 read with the
relevant rules made thereunder, out of the total Directors, two-third of the Directors
shall retire by rotation every year and if eligible, offer themselves for reappointment at
the AGM. Mr. Nikunj Mange (DIN: 08489442) currently Executive Director of the Company and
proposed Re-designed as Managing Director subject to approval of Shareholder is liable to
retire by rotation and being eligible, he has offered himself for re-appointment. The
Board of Directors recommended his re-appointment in their meeting held on August 12, 2026
and the same is being placed before the Members for their approval at the ensuing 53rd
Annual General Meeting of the Company.
Pursuant to Regulation 36(3) of SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015 ("Listing Regulations") read with Secretarial Standards 2 on
General Meetings, a brief profile of Mr. Nikunj Mange is provided as an Annexure-1 of
the Notice of 53rd Annual General Meeting.
DECLARATION OF INDEPENDENCE FROM INDEPENDENT DIRECTORS
Your Company has received declarations from all the Independent Directors confirming
that they meet the criteria of independence as prescribed under regulation 16(1)(b) of
SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the same has
been taken on record by Company.
There has been no change in the circumstances affecting their status as Independent
Directors of the Company.
During the year under review, the Non-Executive Directors of the Company had no
pecuniary relationships or transactions with the Company, other than receiving the sitting
fees
a) APPOINTMENT/ RESGINATION/ REDESIGNATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL
I. DURING THE YEAR UNDER REVIEW
Event |
Particulars |
| Completion of Tenure |
Mrs. Mangala Prabhu (DIN: 06450659) ceased to be a Non-Executive &
Independent Director on the Board of Directors of the Company with effect from closing
hours of September, 27 2025 respectively on completion of her second consecutive term as
an Independent Director |
| Cessation due to death |
Cessation of Mrs. Alaka Keshav Deshpande (DIN: 11238406) as Independent
Director of the Company w.e.f December 30, 2025 |
| Re-appointment |
i) The Nomination and remuneration committee and Board members in its
meeting held on May 16, 2025 considered the re-appointment of Dr. Pankaj J. Shah
(DIN:02836324) as Managing Director of the Company for a period of three (3) years i.e
from August 01, 2025 to July 31, 2028 subject to members approval. |
|
ii) The members of the Company by Postal Ballot via special resolution on
July 10, 2025 approved the re-appointment of Dr. Pankaj J. Shah (DIN:02836324) as Managing
Director of the Company for a period of three (3) years i.e from August 01, 2025 to July
31, 2028 |
| Appointment |
The Nomination and remuneration committee and Board members in its
meeting held on 12.11.2025 considered Mrs. Kiran Raghavendra Awasthi (DIN: 09066721) as an
Additional Independent Director for a First Term of five (5) years w.e.f. November 12,
2025, subject to the approval of the members of the Company and The members of the Company
by Postal Ballot via special resolution on February 05 approved her appointment as
Independent Director from November 12, 2025 up to November 11, 2030 (both days inclusive) |
| Resignation |
Ms. Krupali Shah (Membership No.: A70473), Company Secretary and
Compliance Officer of the Company, tendered her resignation from the position of Company
Secretary and Compliance Officer on March 07, 2026, due to personal reasons. She ceased to
hold the office of Company Secretary and Compliance Officer of the Company with effect
from March 08, 2026. |
II. AFTER THE COMPLETION OF THE YEAR UNDER REVIEW
Event |
Particulars |
Appointment |
Mr. Vaibhav Odhekar was appointed by the Board of Directors as an
Additional Director (Executive Director) of the Company at its Board Meeting held on May
23, 2026 |
Resignation |
Mr. Vaibhav Odhekar resigned as an Additional Director (Executive
Director) on July 25, 2026 |
Resignation |
Mr. Pankaj Shah Resigned on 3rd August from Post of
Managing Director and Chief Executive Officer on 3rd August 2026 |
Appointment |
Mrs. Neetu Maurya was appointed as the Company Secretary and
Compliance Officer of the Company in Board Meeting held on May 23, 2026 with effect
from May 24, 2026. |
KEY MANAGERIAL PERSONNEL (KMP)
In accordance with the provisions of Sections 2(51), 203 of the Companies Act, 2013
read with Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014,
the following are/were the Key Managerial Personnel of the Company:
1. Mr. Balkrishna Talawadekar- Chief Financial Officer
2. Ms. Krupali Shah- Company Secretary resigned with effect from 8th March
2026
3. Mrs. Neetu Maurya - Company Secretary appoint with effect from 24th May
2026
PERFORMANCE EVALUATION
Pursuant to the applicable provisions of the Companies Act, 2013 and Regulations
17(10), 25(4) and of SEBI (Listing Obligations and Disclosure Requirements) Regulations,
2015, the Board of Directors have carried out annual performance Evaluation of:
i. Their own performance as a whole; ii. Individual Directors Performance; and iii.
Performance of all Committees of the Board for the Financial Year 2025-26
In terms of the requirements of Schedule IV of the Act, a separate meeting of
Independent Directors of the Company was held on February 28, 2026. In which the
performance of the Board as a Whole and of its Committees was evaluated by the Board
through a structured questionnaire which covered various aspects such as the composition,
quality and performance of the Board, meetings and procedures, contribution to Board
processes, effectiveness of the functions allocated, relationship with Management,
professional development, adequacy, appropriateness, and timeliness of information etc.
Taking into consideration the responses received from the Individual Directors the
performance of the Board and its Committees was evaluated. The Directors expressed their
satisfaction with the evaluation process.
NOMINATION AND REMUNERATION POLICY
The brief on the policy of nomination and remuneration and other matters provided in
Section 178(3) of the Act have been disclosed in the Corporate Governance Report, which
forms part of the Annual Report of the Company. The Nomination and Remuneration Policy is
also available on the website of the Company and can be accessed through the following web
link:
www.aspiradiagnostics.com/wp-content/uploads/2024/02/Nomination-and-Remuneration-Policy-Aspira-Pathlab.pdf
BOARD MEETINGS
During the year under the review, the Board of Directors met Four (4) times the details
of which are given in the Corporate Governance Report. The intervening gap between the
Meetings was within the period prescribed under the Companies Act, 2013.The dates of the
Board Meeting are as follows:
May 16, 2025
August 12, 2025
November 12, 2025 and
February 10, 2026
COMMITTEES OF THE BOARD
The Board of Directors of your Company have formed various Committees, as per the
provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 and as a part of good corporate governance practices. The
terms of reference and the constitution of those Committees are in compliance with the
applicable laws
In order to ensure focused attention on business, better governance and accountability,
the Board has constituted the following committees:
a) Audit Committee; b) Nomination and Remuneration Committee; c) Stakeholder
Relationship Committee
The details with respect to the Composition, terms of reference, etc. of the aforesaid
committees are given in details in the "Corporate Governance Report" which is
presented in a separa]te section and forms part of the Annual Report of the Company.
AUDIT COMMITTEE
The Audit Committee is constituted as per Regulation 18 of the Listing Regulations read
with Section 177 of the
Companies Act, 2013. Kindly refer section on Corporate Governance, under head 'Audit
Committee' for matters relating to constitution, meetings and functions of this Committee.
NOMINATION AND REMUNERATION COMMITTEE'
The Nomination and Remuneration Committee is constituted in compliance with the
requirements of Regulation 19 of the Listing Regulations read with Section 178 of the
Companies Act, 2013. The details pertaining to its constitution, meetings, terms of
reference etc. is provided under Corporate Governance section under head 'Nomination &
Remuneration Committee'.
STAKEHOLDER RELATIONSHIP COMMITTEE
The Stakeholders' Relationship Committee of the Company is constituted in line with the
provisions of Regulation 20 of the Listing Regulations read with Section 178(5) of the
Companies Act, 2013.The details pertaining to its constitution, meetings, terms of
reference etc. is briefly provided in the Corporate Governance Report under the head
'Stakeholders' Relationship Committee'.
STATUTORY AUDITORS AND AUDITORS REPORT
The Members of the Company in their 51st Annual General Meeting
("AGM") on September 27, 2024, had appointed M/s. Sarda Soni Associates LLP,
Chartered Accountants, (Firm Registration No. 117235W) as the Statutory Auditors of the
Company to hold office for their first term of five (5) years i.e. from the conclusion of
51st AGM till the conclusion of 56th AGM of the Company.
M/s. Sarda Soni Associates LLP, Chartered Accountants, Statutory Auditors have
confirmed that they have not been disqualified to act as Statutory Auditors of the Company
and that their continuation is within the ceiling limit as prescribed under section 139
and 141 of the Companies Act, 2013 and related rules thereto
Further, the Statutory Auditors of the Company have not reported any fraud as specified
under the second provison of Section 143(12) of the Companies Act, 2013 (including any
statutory modification(s) or re- enactment(s) for the time being in force).
The Auditors' Report for the Financial Year ended March 31, 2026, is issued with
unmodified opinion and does not contain any qualification, reservation or adverse remarks.
The Auditors' Report being self-explanatory does not call for any further comments from
the Board of Directors.
SECRETARIAL AUDITOR AND SECRETARIAL AUDIT REPORT
In compliance with the provisions of Section 204 and other applicable provisions of the
Companies Act, 2013, read with Rule 9 of the Companies (Appointment and Remuneration of
Managerial Personnel) Rules, 2014, and Regulation 24A of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015, as amended from time to time, the Board of
Directors, based on the recommendation of the Audit Committee, at its meeting held on May
16, 2025, approved the appointment of M/s. Nilesh A. Pradhan & Co. LLP, Practicing
Company Secretaries, as the Secretarial Auditor of the Company for a period of five (5)
consecutive financial years commencing from April 01, 2025 to March, 31 2030, The said
appointment was approved by the shareholders of the Company at the 52nd Annual General
Meeting held on 26th September 2025.
The firm holds a valid Peer Review Certificate issued by the Institute of Company
Secretaries of India (ICSI). The firm has the necessary qualifications, expertise, and
experience to carry out the Secretarial Audit and to issue the Annual Secretarial
Compliance Report in accordance with applicable laws.
After careful evaluation of the firm's professional competence, independence, and track
record, the Audit Committee and the Board are of the view that M/s. Nilesh A. Pradhan
& Co. LLP is well-suited for the said appointment.
The Secretarial Audit Report for the Financial Year ended March 31, 2026, as issued by
CS Prajakta V Padhye, Practicing Company Secretary, Partner of M/s. Nilesh A. Pradhan
& Co., LLP (Membership No. FCS 7478; CP No 7891) in Form MR-3 is annexed to the Board
report as Annexure III which is self-explanatory and does not contain any
qualification, reservation or adverse remark.
INTERNAL AUDITOR
In compliance with the provisions of Section 138 of the Companies Act, 2013 read with
rule 13 of Companies (Accounts) Rules, 2014 the Board of Directors on the recommendation
of Audit Committee has re-appointed M/s. Vishal J Bhanushali, Chartered Accountants
(FRN:145806W), Chartered Accountants as Internal Auditors of your Company for financial
year 2026-27.
The Audit Committee in its quarterly meetings reviews the internal audit and internal
control systems. The
Company's internal controls commensurate with the size and operations of the business.
Continuous internal monitoring mechanism ensures timely identification and redressal of
issues.
DIRECTOR'S RESPONSIBILITY STATEMENT
Based on the framework of Internal Financial Controls and compliance systems
established and maintained by the Company, the work performed by the Internal Auditors,
Statutory Auditors and Secretarial Auditors, including the Audit of Internal Financial
Controls over financial reporting by the Statutory Auditors and the reviews performed by
Management and the relevant Board Committees, including the Audit Committee, the Board is
of the opinion that the Company's internal financial controls were adequate and effective
during Financial Year 2025-26
In accordance with the requirement of Section 134(5) of the Companies Act, 2013, in
relation to the audited financial statements of the Company for the year ended March 31,
2026, the Board of Directors of the Company confirm that: To the best of their knowledge
and belief and according to the information and explanation obtained by them, your
Directors make the following statements in terms of Section 134(3)(c) read with Section
134(5) of the Companies Act, 2013. a) that in the preparation of the annual accounts for
the financial year ended March, 31 2026 the Indian Accounting Standards (Ind AS) have been
followed and there are no material departures b) such accounting policies have been
selected and applied consistently and the Directors made judgments and estimates that are
reasonable and prudent so as to give a true and fair view of the state of affairs of the
Company as on March 31, 2026 and of the profit of the Company for the year ended on that
date; c) proper and sufficient care is taken for the maintenance of adequate accounting
records in accordance with the provisions of the Companies Act, 2013 for safeguarding the
assets of the Company and for preventing and detecting material fraud and other
irregularities; d) the annual accounts of the Company have been prepared on a going
concern basis; e) proper internal financial controls have been laid down to be followed by
the Company and that such internal financial controls are adequate and were operating
effectively; f) the Directors have devised proper system to ensure compliance with the
provisions of all applicable laws and that such systems were adequate and operating
effectively.
WHISTLE BLOWER MECHANISM
Your Company has adopted and established a vigil mechanism named "Whistle Blower
Policy (WBP)" for directors and employees to report genuine concerns and to deal with
instance of fraud and mismanagement, if any {in compliance with the provisions of Section
177 (10) of the Companies Act, 2013 ('the Act') and Regulation 22 of the SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015).
The Policy provides for adequate safeguards against victimization of employees, who
avail of the mechanism and provides to employees' direct access to the Chairman of the
Audit Committee. It is affirmed that no personnel of the Company have been denied access
to the Audit Committee. The details of the Whistle Blower Policy are explained in the
Corporate Governance Report and also available on your Company's website at the below link
www.aspiradiagnostics.com/wp-content/uploads/2024/02/Whistle-Blowers-Policy.pdf
INSTANCES OF FRAUD, IF ANY, REPORTED BY AUDITORS
During the year under review, Auditors have not reported any instances of frauds
committed in your Company by its Officers or Employees to the Audit Committee and / or to
the Board under Section 143(12) of the Companies Act, 2013.
PREVENTION OF INSIDER TRADING
In order to restrict communication of Unpublished Price Sensitive Information (UPSI),
the Company has adopted Code of Fair Disclosure of Unpublished Price Sensitive Information
in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The said Code
is available on the website of the Company at the Web link:
www.aspiradiagnostics.com/wp-content/uploads/2025/02/Code-of-Practices-Proceduers-For-Fair-Disclosure-of-UPSI.pdf
Further the Company has adopted Structured Digital Database (SDD) in the Company as per
the Regulation 3(5) and 3(6) of SEBI (PIT) Regulations, 2015 and timely freezing the PAN
of Designated Personnel's to avoid the insider tradings.
The Company Secretary of the Company is the Compliance Officer for monitoring adherence
to the said Regulations and in absence of Company Secretary, Chief Financial Officer act
as Compliance Officer for the same.
MANAGEMENT DISUSSION AND ANALYSIS
Pursuant to Regulation 34 read with Schedule V of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015, ('Listing Regulations'), a detailed review of
operations, performance and future outlook of your Company and its business is given in
the Management Discussion and Analysis (MDA) which forms part of this Report. The MDA
report is attached herewith as Annexure-IV to this Annual Report.
CORPORATE GOVERNANCE
Report on Corporate Governance and Certificate by the Secretarial Auditors of the
Company regarding compliance of the conditions of Corporate Governance as stipulated in
Part C of Schedule V of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015, are provided in a separate section and forms part of the Annual Report
of the Company.
In view of the inadequacy of profits during the financial year, the remuneration
payable to the Managing Director/Whole-time Director is proposed in accordance with the
provisions of Section 197, Section 198 and Section II of Part II of Schedule V to the
Companies Act, 2013. The disclosures as prescribed under Schedule V are provided in Notice
of this AGM. The Board is of the opinion that the remuneration proposed is fair,
reasonable and commensurate with the responsibilities entrusted to the appointee and is in
the best interests of the Company.
CODE OF CONDUCT
Pursuant to Regulations 17(5) of the SEBI (LODR) Regulation, 2015, Your Company has
formulated Code of Conduct for its Board of Directors and Senior Management, specifying
duties of a Board Members and Senior Management
Personnel as laid down in the Companies Act, 2013 and the same has been placed on
Company's website at the below link
www.aspiradiagnostics.com/wp-content/uploads/2024/02/code-of-conduct-for-Board-Members-and-Senior-Management-Personnel.pdf
RISK MANAGEMENT COMMITTEE
Pursuant to Section 134 of the Companies Act, 2013, the Company has a risk management
policy in place for identification of key risks to its business objectives, impact
assessment, risk analysis, risk evaluation, risk reporting and disclosures, risk
mitigation and monitoring, and integration with strategy and business planning.
Pursuant to Regulation 21(5) of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations,2015 the constitution of a Risk Management Committee is not
applicable to the Company.
CORPORATE SOCIAL RESPONSIBILITY (CSR)
During the year under review your company has not qualified the criteria of Section 135
of the Companies Act, 2013 to constitute a CSR committee and to spend in CSR activity.
However, your company assure that it will comply with Section 135 when the section will be
applicable on company
DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE PREVENTION, PROHIBITION
AND REDRESSAL) ACT, 2013
Your Company has complied with provisions relating to the constitution of Internal
Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention,
Prohibition and Redressal) Act, 2013.
The details relating to the number of complaints received and disposed off is given
below:
Sr No. Particulars |
|
| 1. Number of complaints of sexual harassment received in the year |
Nil |
| 2. Number of complaints disposed off during the year |
Nil |
| 3. Number of cases pending for more than ninety days |
Nil |
NUMBER OF EMPLOYEES AS ON THE CLOSURE OF FINANCIAL YEAR 2025-26
Sr No. Particulars |
|
| 1. Female |
74 |
| 2. Male |
94 |
| 3. Transgender |
Nil |
DISCLOSURE RELATING TO COMPLIANCE OF THE PROVISIONS OF MATERNITY BENEFIT ACT 1961.
During the year under the review, your Company has complied with the provisions of
Maternity Benefit Act 1961.
ANNUAL RETURN
In accordance with Sections 134(3)(a) & 92(3) of the Companies Act, 2013 read with
Rule 12(1) of the Companies (Management and Administration) Rules, 2014, an extract of
Annual Return of the Company for the Financial Year 2025-26 shall be available on the
website of the Company at www.aspiradiagnostics.com , under the section 'Investor Corner'.
CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTIONS AND FOREIGN EXCHANGE EARNINGS AND OUTGO
The information relating to the conservation of energy, technology absorption foreign
exchange earnings and outgo under section 134(3)(m) of the Companies Act, 2013 read with
Rule 8 of the Companies (Accounts)Rules, 2014 is appended as Annexure- V to this
report.
GREEN INTITATIVE
i) In line with the applicable circulars issued by the Ministry of Corporate Affairs
and the Securities and Exchange Board of India, the Notice of the AGM along with the
Annual Report for the financial year 2025-26 is being sent electronically to those Members
whose email addresses are registered with the Company, Depositories, or Registrar and
Transfer Agent (RTA) unless a member has specifically requested for a physical copy of the
same. ii) For Members whose email addresses are not registered, the Company/RTA will
dispatch a physical letter containing the web link and exact path to access the Notice of
AGM and the Annual Report. The said documents are also available on the Company's website
at www.aspiradiagnostics.com/investor-relation/and can be accessed on the websites of the
Stock Exchange (BSE Limited) at www.bseindia.com as well as on the website of NSDL at www.
evoting.nsdl.com
INTERNAL FINANCIAL CONTROLS
Your Company has in place an adequate internal financial control framework with
reference to financial and operating controls thereby ensuring orderly and efficient
conduct of its business, including adherence to the
Company's policies, safeguarding of its assets, prevention and detection of frauds and
errors, accuracy and completeness of accounting records, and timely preparation of
reliable financial information.
During Financial Year 2025-26, such controls were tested and no reportable material
weakness in the design or operation was observed. The Directors have in the Directors
Responsibility Statement confirmed the same to this effect. The Internal Financial
Controls with reference to financial statements as designed and implemented by the Company
are adequate. During the year under review, no material or serious observations has been
received from the Auditor of the Company for inefficiency or inadequacy of such controls.
COST AUDITOR
Maintenance of cost records and requirement of cost audit as prescribed under the
provisions of Section 148(1) of the Companies Act, 2013 are not applicable to the Company
for the FY 2025-26.
DISCLOSURE RELATED TO INSOLVENCY AND BANKRUPTCY
During the financial year under review, there is no application made and/or no
proceeding pending under the Insolvency and Bankruptcy Code, 2016.
DETAILS OF DIFFERENCE BETWEEN VALUA4TION AMOUNT ON ONE TIME SETTLEMENT AND VALUATION
WHILE AVAILING LOAN FROM BANKS AND FINANCIAL INSTITUTIONS
During the year under review, there has been no one-time settlement of Loans taken from
Banks and Financial Institutions.
SIGNIFICANT/MATERIAL ORDERS PASSED BY THE REGULATORS
Pursuant to the requirement of Section 134(3)(q) of the Companies Act, 2013 read with
Rule 8(5)(vii) of the Companies (Accounts) Rules, 2014, it is confirmed that during the
Financial Year under review, there are no significant/material orders passed by the
Regulators or Courts or Tribunals impacting the going concern status ofyour Company and
its operations in future.
SECRETARIAL STANDARDS
Your Directors confirm that the Secretarial Standards issued by the Institute of
Company Secretaries of India, have been complied with. Your Company has duly complied with
Secretarial Standards on Meetings of the Board of Directors (SS-1) and General Meetings
(SS-2) issued by the Institute of Company Secretaries of India and approved by the Central
Government under Section 118(10) of the Companies Act, 2013.
OTHER DETAILS
Mr. Nikunj Velji Mange, who was associated with the Company as a Director prior to the
completion of the Open Offer, has been classified as a Promoter of the Company upon
completion of the Open Offer. Further, Mr. Jay Arvind Bhanushali has also been classified
as a Promoter of the Company pursuant to the completion of the Open Offer.
ACKNOWLEDGEMENT
Your Company has maintained healthy, cordial and harmonious industrial relations at all
levels. Your Directors place on record their deep appreciation to employees at all levels
for their hard work, dedication and commitment.
The Board place on record its appreciation for the support and co-operation your
Company has been receiving from its investors, customers, vendors, bankers, financial
institutions, business associates, Central & State Government authorities, Regulatory
authorities and Stock Exchanges. Your Board looks forward for the long-term future with
confidence, optimisms and full of opportunities.